STOCK TITAN
  1. Home
  2. Sec-filings
  3. RXRX
  4. [144] RECURSION PHARMACEUTICALS, INC. SEC Filing

Recursion director plans sale of 30K RXRX shares

RECURSION PHARMACEUTICALS, INC.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

RECURSION PHARMACEUTICALS, INC. (RXRX) director Blake Borgeson has filed a Form 144 indicating an intent to sell 30,000 Class A shares of Recursion through Fidelity Brokerage Services LLC, with an approximate aggregate value of $100,200. The shares were originally acquired on 09/19/2017 as Founders Shares received as compensation. The notice also lists prior Rule 144 sales over the last three months.

Positive

  • None.

Negative

  • None.
Proposed shares to be sold 30,000 Class A shares Shares associated with Blake Borgeson in current Form 144 notice
Proposed aggregate sale price $100,200.00 Approximate aggregate value of 30,000 Class A shares in current notice
Acquisition date of shares 09/19/2017 Date the 30,000 Founders Shares were acquired as compensation
Shares sold 06/02/2026 30,000 Class A shares Past 3-month sale for aggregate proceeds of $110,400.00
Proceeds 06/02/2026 sale $110,400.00 Aggregate proceeds from sale of 30,000 Class A shares
Shares sold 07/07/2026 40,000 Class A shares Past 3-month sale for aggregate proceeds of $158,500.00
Proceeds 07/07/2026 sale $158,500.00 Aggregate proceeds from sale of 40,000 Class A shares
Proceeds 08/04/2026 sale $97,500.00 Aggregate proceeds from sale of 30,000 Class A shares
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Founders Shares financial
"Class A | 09/19/2017 | Founders Shares | Issuer"
Founders shares are a special block of a company’s stock originally given to the people who started the business; they often carry extra voting power or favorable terms compared with regular shares. For investors, these shares matter because they concentrate control and influence how future funding, ownership dilution, and decision-making will play out—think of founders shares as the steering wheel that can steer a company’s direction even as more passengers (investors) climb aboard.
attorney-in-fact regulatory
"as attorney-in-fact for Blake C. Borgeson"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.
aggregate sale price financial
"| 30000 | 100200.00 | 535342170 |"

FAQ

What does the Form 144 filing for RXRX disclose about Blake Borgeson?
It discloses that director Blake Borgeson has notified of a proposed sale of 30,000 Class A shares of Recursion Pharmaceuticals, Inc. under Rule 144, to be executed through Fidelity Brokerage Services LLC, with an approximate aggregate value of $100,200.

How many RXRX shares are proposed to be sold in this Form 144?
The filing indicates a proposed sale of 30,000 Class A shares of Recursion Pharmaceuticals, Inc., associated with Blake Borgeson, using Fidelity Brokerage Services LLC as broker, with an approximate aggregate value of $100,200.

What prior RXRX share sales does Blake Borgeson report in the last three months?
The notice lists three prior Class A share sales: 30,000 shares for $110,400 on 06/02/2026, 40,000 shares for $158,500 on 07/07/2026, and 30,000 shares for $97,500 on 08/04/2026.

How were the RXRX shares in this Form 144 originally acquired?
The 30,000 Class A shares covered by this Form 144 were acquired on 09/19/2017 as Founders Shares from the issuer, described in the filing as received as Compensation.

Which broker is handling the proposed RXRX share sale in this Form 144?
The proposed sale of 30,000 Class A shares of Recursion Pharmaceuticals, Inc. is listed as being handled by Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917.

On which market are the RXRX shares in this Form 144 listed?
The Class A shares of Recursion Pharmaceuticals, Inc. referenced in the Form 144 are identified as traded on NASDAQ, with CUSIP 535342170 noted in the securities information section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Source: View Original Filing on SEC EDGAR